ASND:NSD-Ascendis Pharma AS (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 177.55

Change

+3.86 (+2.22)%

Market Cap

USD 9.13B

Volume

0.36M

Analyst Target

USD 176.55
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-2.03 (-0.46%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

-1.86 (-0.38%)

USD 65.38B
ARGX argenx NV ADR

+7.09 (+1.24%)

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

+2.69 (+0.88%)

USD 32.75B
ONC BeiGene, Ltd.

-1.27 (-0.49%)

USD 27.70B
RPRX Royalty Pharma Plc

+0.31 (+0.93%)

USD 18.35B
SMMT Summit Therapeutics PLC

+0.17 (+0.87%)

USD 13.53B
INSM Insmed Inc

-0.95 (-1.29%)

USD 11.84B
INCY Incyte Corporation

-0.18 (-0.27%)

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

-0.84 (-1.50%)

USD 11.29B

ETFs Containing ASND

MEDI Harbor Health Care ETF 19.21 % 0.00 %

+0.12 (+-0.22%)

USD 0.01B
WELL:PA HAN-GINS Indxx Healthcare.. 9.63 % 0.00 %

-0.01 (-0.22%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 9.63 % 0.00 %

+0.01 (+-0.22%)

N/A
SYNB Putnam Biorevolution ETF 4.03 % 0.00 %

-0.17 (-0.22%)

USD 4.89M
BBP Virtus LifeSci Biotech Pr.. 2.26 % 0.79 %

+0.20 (+-0.22%)

USD 0.02B
MSSM Morgan Stanley Pathway Sm.. 1.10 % 0.00 %

-0.10 (-0.22%)

N/A
MEU:CA 0.00 % 0.61 %

N/A

N/A
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.01 (-0.22%)

N/A
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 28.97% 83% B 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.97% 83% B 88% B+
Trailing 12 Months  
Capital Gain 28.19% 81% B- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.19% 81% B- 80% B-
Trailing 5 Years  
Capital Gain 25.94% 82% B 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.94% 82% B 55% F
Average Annual (5 Year Horizon)  
Capital Gain 1.68% 55% F 49% F
Dividend Return 1.68% 55% F 44% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.85% 89% A- 63% D
Risk Adjusted Return 6.05% 59% D- 43% F
Market Capitalization 9.13B 98% N/A 92% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.